登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《IJAA，3月13日，Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-03-16

  • Teicoplanin: an alternative drug for the treatment of coronavirus COVID-19?

    Sophie AlexandraBaron, ChristianDevaux, PhilippeColson, DidierRaoult, Jean-MarcRolain

    Show more

    https://doi.org/10.1016/j.ijantimicag.2020.105944

    Abstract

    In December 2019, a new coronavirus, named SARS-CoV-2, has emerged from China causing pneumonia outbreaks first in the Wuhan region and have now spread worldwide because of its probable high transmission efficiency. Due to the lack of efficient and specific treatments and the need to contain the epidemic, drug repurposing appears to be the best tool to find therapeutic solution. Chloroquine, remdesivir, lopinavir, ribavirin or ritonavir have shown efficacy to inhibit coronavirus in vitro.

  • 原文来源：https://www.sciencedirect.com/science/article/abs/pii/S0924857920300947
68浏览量
原文链接
相关报告

  • 《IJAA，3月12日，New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19?》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-13
    • New insights on the antiviral effects of chloroquine against coronavirus: what to expect for COVID-19? Christian A.Devaux, Jean-MarcRolain, PhilippeColson, DidierRaoult Show more https://doi.org/10.1016/j.ijantimicag.2020.105938 Abstract Recently, a novel coronavirus (2019-nCoV), officially known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment measures, the spread of this virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary infection in humans. The efforts of international health authorities have since focused on rapid diagnosis and isolation of patients as well as the search for therapies able to counter the most severe effects of the disease.
    41浏览量
    原文链接

  • 《ChinaXiv，3月6日，Effective Treatment of Severe COVID-19 Patients with Tocilizumab》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-03-07
    • Effective Treatment of Severe COVID-19 Patients with Tocilizumab 提交时间： 2020-03-05 作者： Xu, Xiaoling 1 ; Han, Mingfeng 2 ; Li, Tiantian 1 ; Sun, Wei 2 ; Wang, Dongsheng 1 ; Fu, Binqing 3,4 ; Zhou, Yonggang 3,4 ; Zheng, Xiaohu 3,4 ; Yang, Yun 1 ; Li, Xiuyong 2 ; Zhang, Xiaohua 2 ; Pan, Aijun 1 ; Wei, Haiming 3,4 ; 内容摘要 Background: In December 2019, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in Wuhan, China, which spread rapidly and has become a world-wide public health challenge. We aimed to assess the efficacy of tocilizumab in severe patients with Corona Virus Disease-19 (COVID-19) and seek a new therapeutic strategy. Methods: The patients diagnosed as severe or critical COVID-19 in The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital) and Anhui Fuyang Second People’s Hospital were given tocilizumab in addition to routine therapy between February 5 and February 14, 2020. *注，本文为预印本论文手稿，是未经同行评审的初步报告，其观点仅供科研同行交流，并不是结论性内容，请使用者谨慎使用.
    59浏览量
    原文链接